Peter Goadsby, MB BS

Neurologist and headache specialist

Dr. Peter Goadsby, a neurologist, specializes in the diagnosis and treatment of headache disorders, including migraines and cluster headache and other forms of chronic daily headache. He is one of the world's leading headache experts and researchers.

Goadsby came to UCSF from the Institute of Neurology at University College London, National Hospital for Neurology and Neurosurgery and Hospital for Sick Children, Great Ormond Street, London, England. His research focuses on the mechanisms and management of head pain, with a special interest in migraine and trigeminal autonomic cephalalgias. His studies aim to understand the parts of the brain involved in headache and from this to derive new approaches to treatment. He earned a medical degree at the University of New South Wales School of Medicine, completed a residency in neurology at the Prince of Wales Hospital and completed a fellowship in neurology at the National Hospital for Nervous and Mental Diseases in London. He completed post-doctoral work in laboratories in New York and Paris.


Headache Center
2330 Post St., Sixth Floor
San Francisco, CA 94115
Phone: (415) 353-8393
Fax: (415) 353-9539

Hours: Monday to Friday
9 a.m. – 5 p.m.

Conditions & Treatments

Academic Title


More about Peter Goadsby


University of New South Wales Doctorate Program, Neurosciences 1983
University of New South Wales School of Medicine 1985


Prince Henry, Prince of Wales Hospital, Medicine 1987
Prince Henry, Prince of Wales Hospital, Neurology 1988
Prince Henry, Prince of Wales Hospital, Clinical Neurophysiology 1989


National Hospital for Nervous and Mental Diseases, Neurology 1990

Selected Research and Publications

  1. Holland PR, Goadsby PJ. Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy. Neurotherapeutics. 2018 Mar 19.
  2. Karsan N, Palethorpe D, Rattanawong W, Marin JC, Bhola R, Goadsby PJ. Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK. Eur J Neurol. 2018 Mar 07.
  3. Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018 Apr; 38(5):815-832.
  4. Ong JJY, Wei DY, Goadsby PJ. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs. 2018 Mar; 78(4):411-437.
  5. Goadsby PJ, Picard H, Mikol DD. Preventive Therapies for Chronic Migraine. N Engl J Med. 2018 02 22; 378(8):774-5.
  6. Wei DY, Greenwood FS, Murgatroyd FD, Goadsby PJ. Case Report of the Safety Assessment of Transcranial Magnetic Stimulation Use in a Patient With Cardiac Pacemaker: To Pulse or Not to Pulse? Headache. 2018 Feb; 58(2):295-297.
  7. Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol. 2018 Feb 01; 75(2):187-193.
  8. Puledda F, Schankin C, Digre K, Goadsby PJ. Visual snow syndrome: what we know so far. Curr Opin Neurol. 2018 Feb; 31(1):52-58.
  9. Puledda F, Goadsby PJ, Prabhakar P. Treatment of disabling headache with greater occipital nerve injections in a large population of childhood and adolescent patients: a service evaluation. J Headache Pain. 2018 Jan 16; 19(1):5.
  10. Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. 2018 Jan 01; 333102418762525.
  11. Messina R, Goadsby PJ. CGRP - a target for acute therapy in migraine: Clinical data. Cephalalgia. 2018 Jan 01; 333102418768095.
  12. Goadsby PJ, de Coo IF, Silver N, Tyagi A, Ahmed F, Gaul C, Jensen RH, Diener HC, Solbach K, Straube A, Liebler E, Marin JC, Ferrari MD. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. Cephalalgia. 2018 Apr; 38(5):959-969.
  13. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017 11 30; 377(22):2123-2132.
  14. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017 11 30; 377(22):2113-2122.
  15. Özge A, Abu-Arafeh I, Gelfand AA, Goadsby PJ, Cuvellier JC, Valeriani M, Sergeev A, Barlow K, Uludüz D, Yalin OÖ, Faedda N, Lipton RB, Rapoport A, Guidetti V. Experts' opinion about the pediatric secondary headaches diagnostic criteria of the ICHD-3 beta. J Headache Pain. 2017 Nov 29; 18(1):113.
  16. Özge A, Faedda N, Abu-Arafeh I, Gelfand AA, Goadsby PJ, Cuvellier JC, Valeriani M, Sergeev A, Barlow K, Uludüz D, Yalin OÖ, Lipton RB, Rapoport A, Guidetti V. Experts' opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents. J Headache Pain. 2017 Nov 23; 18(1):109.
  17. Tso AR, Marin J, Goadsby PJ. Noninvasive Vagus Nerve Stimulation for Treatment of Indomethacin-Sensitive Headaches. JAMA Neurol. 2017 Oct 01; 74(10):1266-1267.
  18. Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology. 2017 Sep 19; 89(12):1237-1243.
  19. Tso AR, Goadsby PJ. Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention? Curr Treat Options Neurol. 2017 Aug; 19(8):27.
  20. Gelfand AA, Qubty W, Goadsby PJ. Pediatric Migraine Prevention-First, Do No Harm. JAMA Neurol. 2017 Aug 01; 74(8):893-894.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.